AHSZX Fees and Costs — Alger Health Sciences Fund, Class Z
Data updated: 2026-09-25
The net expense ratio is 0.76%: a 0.55% management fee plus 0.27% other expenses, less a 0.06% fee waiver. There are no sales loads or redemption fees. In fiscal 2025 the fund paid $243K in broker commissions, 0.3215% of average net assets, and portfolio turnover was 289%.
AHSZX Fees and Expenses
Annual operating expenses and sales charges of AHSZX. Prospectus, as of October 31, 2025.
| Annual operating expenses | |
|---|---|
| Management fee | 0.55% |
| 12b-1 fee | 0.00% |
| Other expenses | 0.27% |
| Gross expense ratio | 0.82% |
| Fee waiver | −0.06% |
| Net expense ratio | 0.76% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | Yes |
| Waived fees subject to recoupment | Yes |
AHSZX Costs Over Time
On $10,000 invested in AHSZX, assuming 5% a year before costs, total costs come to $675 over 5 years, cutting the return by 1.14% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.76%) | $80 | $249 | $431 |
| Trading costs (broker commissions) | $34 | $105 | $182 |
| Lost growth on money paid in costs | $0 | $18 | $62 |
| Total costs | $114 | $372 | $675 |
| Value after costs | $10,386 | $11,205 | $12,087 |
| Impact on return, per year | 1.14% | 1.14% | 1.14% |
AHSZX Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending October 31, 2025.
- Explicit cost rate (commissions ÷ average net assets): 0.3215%
- Total broker commissions: $243K
- Bought from dealers (principal trades, not a cost): $2.0M
- Portfolio turnover (prospectus): 289%
- Securities lending: none during the year
AHSZX Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| Pershing LLC | $64K | 29.41% |
| Fred Alger & Company, LLC | $47K | 21.71% |
| Merrill Lynch, Pierce, Fenner & Smith Incorporated | $46K | 21.19% |
| DINOSAUR FINANCIAL GROUP, L.L.C | $17K | 7.78% |
| NATIONAL FINANCIAL SERVICES LLC | $14K | 6.33% |
| Instinet LLC | $7K | 3.36% |
| CANTOR FITZGERALD & CO. | $7K | 3.06% |
| J.P. Morgan Securities LLC | $6K | 2.58% |
| STIFEL, NICOLAUS & CO INC | $6K | 2.56% |
| JEFFERIES LLC | $4K | 2.02% |
AHSZX Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| PERSHING LLC | $606K | 30.99% |
| Forte Biosciences | $485K | 24.81% |
| J.P. Morgan Securities LLC | $437K | 22.33% |
| JEFFERIES LLC | $298K | 15.23% |
| BARCLAYS CAPITAL, INC. | $129K | 6.62% |
| Merrill Lynch, Pierce, Fenner & Smith Incorporated | $252 | 0.01% |
| Prosetta Biosciences, Inc. | $17 | 0.00% |
| BNY MELLON CAPITAL MARKETS, LLC | $0 | 0.00% |
Alger Health Sciences Fund Share Classes
Net expense ratio and maximum front-end load of each share class, cheapest first.
| Ticker | Class | Net expense ratio | Front load |
|---|---|---|---|
| AHSZX | Class Z | 0.76% | — |
| AHSAX | Class A | 1.17% | 5.25% |
| AHSCX | Class C | 1.96% | none |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.